Technical Analysis for ALPMY - Astellas Pharma Inc

Grade Last Price % Change Price Change
grade A 15.79 -0.06% -0.0100
ALPMY closed down 0.06 percent on Monday, October 21, 2019, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ALPMY trend table...

Date Alert Name Type % Chg
New Uptrend Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
Volume Surge Other -0.06%
Narrow Range Bar Range Contraction -0.06%
Upper Bollinger Band Walk Strength -0.06%
Inside Day Range Contraction -0.06%
Above Upper BB Strength -0.06%
Overbought Stochastic Strength -0.06%

Older signals for ALPMY ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. It also provides Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. In addition, it offers Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, enfortumab vedotin, zolbetuximab, roxadustat, and fezolinetant for oncology indications. The company has a collaboration with Actinium Pharmaceuticals, Inc. to apply Actinium warhead enabling technology platform for generating Actinium radio-conjugates with various Astellas targeting agents. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Chemistry Medicine Diabetes Hypertension Prostate Cancer Osteoporosis Chronic Obstructive Pulmonary Disease Organic Chemistry Non Small Cell Lung Cancer Mitsubishi Ufj Financial Group Benign Prostatic Hyperplasia Lactams Overactive Bladder Exports Pharmaceutical Products Hypercholesterolemia Hyperplasia Adult Bronchial Asthma Astellas Pharma Enzalutamide Tacrolimus Tamsulosin Treatment For Hypertension Treatment For Non Small Cell Lung Cancer Treatment For Osteoporosis Treatment Of Prostate Cancer
Is ALPMY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 16.695
52 Week Low 12.41
Average Volume 70,687
200-Day Moving Average 14.249
50-Day Moving Average 14.1485
20-Day Moving Average 14.5647
10-Day Moving Average 15.0283
Average True Range 0.2466
ADX 25.76
+DI 53.2555
-DI 14.8156
Chandelier Exit (Long, 3 ATRs ) 15.1602
Chandelier Exit (Short, 3 ATRs ) 14.4298
Upper Bollinger Band 15.8983
Lower Bollinger Band 13.2311
Percent B (%b) 0.96
BandWidth 18.31277
MACD Line 0.4282
MACD Signal Line 0.2524
MACD Histogram 0.1758
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.8800
Resistance 3 (R3) 15.8733 15.8367 15.8650
Resistance 2 (R2) 15.8367 15.8137 15.8400 15.8600
Resistance 1 (R1) 15.8133 15.7996 15.8250 15.8200 15.8550
Pivot Point 15.7767 15.7767 15.7825 15.7800 15.7767
Support 1 (S1) 15.7533 15.7537 15.7650 15.7600 15.7250
Support 2 (S2) 15.7167 15.7396 15.7200 15.7200
Support 3 (S3) 15.6933 15.7167 15.7150
Support 4 (S4) 15.7000